Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.50 | N/A | +127.27% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.50 | N/A | +127.27% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed cautious optimism about the company's future, focusing on the positive EPS surprise. They did not provide specific revenue guidance.
Management highlighted the strong performance in EPS despite the lack of revenue guidance.
They emphasized ongoing efforts to enhance product pipeline and partnerships.
Ligand Pharmaceuticals reported a strong EPS performance, exceeding expectations significantly. However, the stock reacted negatively, declining by 0.55%. Investors may be concerned about the lack of revenue data and guidance, which could indicate uncertainty about future growth prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMKOR TECHNOLOGY INC
Aug 1, 2016